Francis Medical concludes first commercial procedures with Vanquish system

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
Morningstar

Francis Medical Announces First Commercial Procedure with the Vanquish® Water Vapor System for Prostate Tissue Ablation

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at ...

Scan that makes prostate cancer glow reduces need for invasive tests

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests. The imaging test highlights aggressive prostate cancer cells, reducing the ...
Business Insider

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...